1Bucala R,Vlasaam H.Advanced glycosylation end products in diabetic renal and vascular disease[J].Am J Kidney Dis,1995,26 (6):875-888.
2Lefebvre PJ,Scheen AJ.The postprandial state and risk of cardiovascular dise.ase[J].Diabetic Medicine,1998,15 (Suppl.4):S63-S68.
3Verena KL,Ulrich S,Andreas N,et al.High glucose-induced transforming growth factor β1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells[J].J Clin Invest,1998,101 (1):160-169.
4Saltiel AR,Kahn CR.Insulin signalling and the regulation of glucose and lipid metabolism[J].Nature,2001,414 (6865):799-806.
5Koya D,King GL.Protein kinase C activation and the development of diabetic complications[J].Diabetes,1998,47(6):859-66.
6Ahmad FK,He Z,King GL.Molecular targets of diabetic cardiovascular complications[J].Curr Drug Targets,2005,6(4):487-494.
7Brownlee M.The pathobiology of diabetic complications:a unifying mechaniam[J].Diabetes,2005,54(6):1615-1625.
9Woodman RJ,Chew GT,Watts GF.Mechanisms,significance and treatment of vascular dysfunction in type 2 diabetes mellitus:focus on lipid-regulating therapy[J].Drugs,2005,65 (1):31-74.
10Ruiz Ortega M,Egldo J.Angiotensin Ⅱ modulates cell growthrelated events and synthesis of matrix protein in renal interstirial fiborblasts[J].Kidney Int,1997,52(6):1497-1510.
